For example, in a study that followed 2377 patients receiving angiotensin-converting enzyme inhibitors (ACEI) and 1780 patients receiving angiotensin II receptor blockers (ARB) for 12 years [77], all-cause dementia risks were reduced in individuals who received ACEIs and ARBs by 26% and 40%, respectively. The gene discussed is ACE; the disease is dementia.